

Disclaimer



This presentation has been prepared by PolyNovo Limited and is provided for general information purposes only. No party other than PolyNovo has authorised or caused the issue of this document, or takes responsibility for, or makes any statements, representations or undertakings in this presentation.


This presentation is not intended to be relied upon as advice to investors or potential investors and does not take into account the investment objectives, financial situation or needs of any particular investor. PolyNovo Limited makes no warranty or representation (express or implied) as to the accuracy, reliability or completeness of the information contained in this presentation. Specifically, several matters referred to in the presentation remain under investigation and are subject to change or even elimination, depending on further research and investigation. Further, any opinions (including any forward-looking statements) expressed in this presentation are subject to change without notice. PolyNovo and its directors, officers, employees, advisers and agents shall have no liability (including liability to any person by reason of negligence or negligent misstatement) for any statements, opinions, information or matters (express or implied) arising out of, or contained in or derived from, or for any omissions from this presentation, except liability under statute that cannot be excluded.

This presentation, including the information contained in this disclaimer, does not form part of any offer, invitation or recommendation in respect of shares, or an offer, invitation or recommendation to sell, or a solicitation of any offer to buy, shares in the United States, or in any other jurisdiction in which, or to any person to whom, such an offer would be illegal.

This presentation may include forward-looking statements. Forward-looking statements are only predictions and are subject to known and unknown risks, uncertainties and assumptions, many of which are outside the control of PolyNovo. Actual values, results or events may be materially different to those expressed or implied in this presentation depending on a range of factors. Given these uncertainties, recipients are cautioned not to place reliance on forward-looking statements. No representation or warranty (express or implied) is made by PolyNovo or any of its directors, officers, employees, advisers or agents that any forecasts, projections, intentions, expectations or plans set out in this presentation will be achieved.



PolyNovo¹



Innovation, emanating from frustration with existing standard of care



2002

The Bali bombing killed 202, critically injured 209. Australian survivors were repatriated to major Burns units for treatment. Large, delayed and colonized wounds required dermal substitutes, but the prevalent biological standard of care carried risk of infection and rejection. Prof. John Greenwood (Burns Unit, Royal Adelaide Hospital) sought a synthetic alternative



Australian research agency CSIRO developed a family of polymers - synthetic material that could safely biodegrade and be metabolized by the human body -- for use in implantable medical devices.

























Bali Bombing CSIRO developed a family of polymers CSIRO/PolyNovo collaboration with Prof. John Greenwood results in development of NovoSorb® BTM Pre-clinical studies and factory established in Port Melbourne. First patient treated with NovoSorb BTM.

NovoSorb BTM: US 510(k) clearance

NovoSorb BTM: Australian TGA registration, India market authorization

Receives European CE Mark and US, FDA Breakthrough Device Designation

NovoSorb BTM:

BARDA, US FDA partnership for Burns Pivotal trial NovoSorb MTX: US 510(K) clearance

Market access in 37 countries



Disrupting US\$2.4B advanced skin substitute market



	Underserved category of critical need	 Unmet global need for advanced skin substitutes. Many products are fraught with issues around tissue origin, complex supply chain and manufacturing, regulatory and licensing challenges and religious considerations, restricting global access. There are considerations around use including infection, pain and dressing changes. Category caters to ~ 800 MM / 8 B population today and are out of reach for many societies.
	Simple, transformative solution	 NovoSorb® BTM, designed by a Burn Surgeon and Polymer chemist, is an immunologically inert, biocompatible dermal foam designed to resorb after enabling the body's natural healing process. Demonstrated excellent patient outcomes including restoration of form, function, an improved cosmesis and reduced complexity for operating teams. Designed for manufacturability and global scale at a much lower cost compared to current standard of care in the US\$2.4 B advanced skin substitute market in 2023*.
	Genius technology, approved products, global presence	 Robust portfolio of intellectual property and trade secrets including 42 issued patents (including on drug and antimicrobial elution, through 2038) NovoSorb® BTM: FDA cleared in 2015, registered and sold in 37 countries. NovoSorb® MTX: FDA cleared in 2022. In addition to the graftable product range(BTM, MTX), a pipeline of implantable products under development.
	Attractive business profile	 NovoSorb® BTM is the market leader in AU, NZ, UK, and Germany and is quickly becoming the standard of care for burns/trauma in the US. 120 patient Burns Pivotal RCT is underway and is well-past the mid-way point for recruitment. 200+ independent, peer reviewed publications and case series have driven rapid adoption.
	Capital efficient, profitable, primed for hyper growth	 Simple manufacturing footprint to support global scale. Demonstrable outcomes, professional enthusiasm, and lean, focused execution is driving hypergrowth. PolyNovo® USA is already a 20% plus EBITDA business. Following successful capital raise in Nov 2022, the business has ~US\$31 MM + in cash and equivalent, with minimal cash burn. Geography, channel and/or specific indication alliances are expected to open multi-billion-dollar opportunities.



NovoSorb®: Simple. Elegant. Transformative





Macro to Micro wounds:


NovoSorb BTM's matrix organizes a large wound (macrowound) into a series of interconnected small wounds (microwounds). The body easily heals small wounds, promoting organized, regenerative healing.

- Biocompatible
- Resorbable

Optimized Regenerative Healing







- 100% synthetic, maintains integrity over time and resistant to shear forces.
- Clinically shown to be robust in presence of infection.
- Flexible, allowing clinicians to skin graft at their convenience, in stages or all at once.
- Virtually unlimited in its supply or consistency unlike biologics.
- Used by a variety of Surgeons including Plastic, Reconstructive, Trauma and General

Shown to minimize scarring. Restores form and function.



Robust IP Portfolio

PolyNovo has IP Protection for 9 Patent families (incl. 42 patents & 23 patent applications) in a broad range of countries including commercial destinations.

These incl. protection for compositions of matter, as well as their general and specific medical use in applications including stents, orthopedic repair, wound repair, hernia and breast reconstruction.

The patents and applications are fully owned by PolyNovo, providing protection for company's technologies until as far out as **2038**.


F

PolyNovo

6

NovoSorb[®]: disrupting several attractive addressable markets






Source: Global Data 2022, Zion reports 2023 M – 000; MM – 000,000; B – Billion



Global strategy on a page:









8

Disciplined execution: vectors for growth




New products Geographic expansion New indications Capacity expansion and partnerships Investing in R&D capability Surgeon led insights and Doubled production output in FY innovation are driving new 2023 and will double again in FY indications and applications 2024. NovoSorb MTX received FDA Hong Kong bevond burns & trauma - i.e.. 510(k) clearance on 19 necrotizing fasciitis, oncological Investing in manufacturing September 2022. excisions, hidradenitis suppurativa, limb expansion, which will allow us salvage, trade-off for certain service demand up to US\$350 Extension of NovoSorb MTX microsurgery procedures, in addition to MM by 2026 (approximately 5 Diabetic Foot ulcers, Vascular, and BTM portfolio, to include times current production volumes). Pressure. Sacral ulcers..etc. India France surgeon-led innovations (thickness, antimicrobial Office space adjacent to current In addition to graftable indications, properties) planned in FY24. premises already deployed to we are working with surgeons to support R&D activity and co-create implantable solutions for Exploring R&D and commercial corporate functions. simple and complex Hernia, Abdominal partnerships to enable speed to wall reconstruction, Breast Spain market. reconstruction..etc.



Disciplined execution: shifting the standard of care





US FDA has cleared NovoSorb BTM wound dressing for management of wounds including; partial and full thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic and vascular ulcers, surgical wounds (donor sites/grafts, post Moh's surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, second degree burns and skin tears) and draining wounds



PolyNovo^a


* Seeking alliances

Standard of care or market leader


Market entry options being evaluated


Accelerating Global Impact











US business profitable standalone.

\$US 783 MM | Market Capitalization, 5 Jan 2024

At constant AUD/USD Exchange rate of 0.7000, FY – July to June, M – 000; MM – 000,000; B – Billion





